Recent Updates
Recently added Catalysts
BBIO

BridgeBio Pharma's QED Therapeutics Announces Dosing Of First Patients In Phase 3 And Phase 2 Clinical Trials Of Infigratinib In Tumors With FGFR Genetic Alterations

Thursday, March 12, 2020 1 min read
Key Takeaway: BridgeBio Pharma's QED Therapeutics Announces Dosing Of First Patients In Phase 3 And Phase 2 Clinical Trials Of Infigratinib In Tumors With FGFR Genetic Alterations

Full Press Release Details

BridgeBio Pharma's QED Therapeutics Announces Dosing Of First Patients In Phase 3 And Phase 2 Clinical Trials Of Infigratinib In Tumors With FGFR Genetic Alterations.
Tags: BBIO Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Mar 12, 2020